Semaglutide and tirzepatide possibly associated with ophthalmic complicationsCase series describes the rare development of nonarteritic anterior ischemic optic neuropathy (NAION) in new users of semaglutide or tirzepatide. Plecanatide approved as a new option for chronic idiopathic constipation in adultsTrulance (plecanatide) is now indicated for the treatment of chronic idiopathic constipation in adults. Can infrequent zoledronate dosing in early postmenopause prevent fractures? Study examines zoledronate dosing at baseline and at five years to determine effects on vertebral fracture prevention in early postmenopausal women. NDSAC releases final recommendations for cetirizine in children Effective Jan. 21, pharmacists should take note of these recommendations for cetirizine or its salts. POP QUIZ: Constella for constipation in children Constella (linaclotide) capsules were recently approved by Health Canada for use in children with constipation. New guidance on caring for newborns at risk of withdrawal due to parental substance use The Canadian Pediatric Society provides updated evidence-based advice as incidence of neonatal abstinence syndrome is rising. Emergency contraception pill could be an alternative to mifepristone for abortions, study suggests Now used in two-thirds of U.S. abortions, mifepristone blocks a hormone needed to sustain a pregnancy. It’s typically used with misoprostol, which causes contractions and bleeding. Oxytocin nasal spray helps combat apathy in frontotemporal dementia: study Caregivers noticed changes in behaviour with treatment over six weeks. Recall: Health Canada pulls compounded semaglutide over unauthorized ingredient Novo Nordisk Canada has also warned that compounded semaglutide may expose patients to health risks. Adverse drug events in outpatient settings ADEs in the outpatient setting are common, occuring in approximately 5% of patients. Of these, 22% are considered preventable. First Previous 29 30 31 32 33 Next Last
